Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Serina TherapeuticsSER -3.69%12 EV-to-OCF is -0.82 as of Jul. 24, 2026. GuruFocus rates SER with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,411 Biotechnology companies, Serina Therapeutics ranks worse than 64.21% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Serina Therapeutics's Enterprise Value is $14.93 Mil.
Serina Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-18.20 Mil. Therefore, Serina Therapeutics's EV-to-OCF for today is -0.82.
The historical rank and industry rank for Serina Therapeutics's EV-to-OCF or its related term are showing as below:
SER'
s EV-to-OCF Range Over the Past 10 Years
Min: -44.05 Med: -5.17 Max: -0.76
Current: -0.82
During the past 5 years, the highest EV-to-OCF of Serina Therapeutics was -0.76. The lowest was -44.05. And the median was -5.17.
SER's EV-to-OCF is ranked worse than 64.21% of 1411
companies
in the Biotechnology industry
Industry Median: -3.32
vs SER: -0.82
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Serina Therapeutics's PE Ratio (TTM) for today is calculated as:
Serina Therapeutics's share price for today is $2.09.
Serina Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Serina Therapeutics EV-to-OCF Related Terms
Serina Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Serina Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Serina Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Serina Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Serina Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Serina Therapeutics's EV-to-OCF falls into.
Serina Therapeutics's current Enterprise Value is $14.93 Mil.
Serina Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Serina Therapeutics (SER) has a EV-to-OCF of -0.82 as of Jul. 24, 2026. According to the industry distribution chart, Serina Therapeutics ranks #906 out of 1411 companies in the Biotechnology industry, placing it in the top 64.2%.
Is Serina Therapeutics' EV-to-OCF too high?
Serina Therapeutics' current EV-to-OCF is -0.82. Based on the distribution chart, Serina Therapeutics ranks #906 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Serina Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' EV-to-OCF compare to NRSN and IGC?
According to the Biotechnology industry distribution chart, Serina Therapeutics ranks #906 out of 1411 companies for EV-to-OCF. This places Serina Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Serina Therapeutics's current EV-to-OCF is -0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (SER) has a current EV-to-OCF of -0.82. The current EV-to-OCF is -0.82. Serina Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Serina Therapeutics (SER), the current EV-to-OCF is -0.82 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
12GF Score
Get the complete analysis for SER
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SER has been successfully added to your 
